GLP-1 News & Research
Policy changes, regulatory news, and new study results.
FDA Warns Novo Nordisk: What Ozempic Patients Should Know
The FDA issued a warning letter to Novo Nordisk over unreported potential side effects. Here is what it actually means for patients taking Ozempic or Wegovy.
GLP-1 Medications and Heart Health: What the Research Shows
GLP-1 medications do more than help you lose weight. Major clinical trials show they cut cardiovascular risk, even without a diabetes diagnosis.
FDA Approves Wegovy HD (7.2 mg): What the Higher Dose Does
The FDA approved Wegovy HD, a higher 7.2 mg semaglutide dose showing 21% average weight loss. Availability, eligibility, and how it compares.
Are Compounded GLP-1 Medications Going Away in 2026?
The cheap compounded GLP-1 era is over, and the FDA wants it gone for good. Here's what patients can do about semaglutide and tirzepatide now.
GLP-1 Weight Loss Results: What the Latest Studies Show
Clinical trials and real-world data show strong weight loss on GLP-1 drugs. Key findings on semaglutide and tirzepatide effectiveness summarized.